Immuno 1 IgG 115 + Gliadin

Overview

The Immuno 1 IgG 115 + Gliadin test analyses IgG antibodies related to a comprehensive set of 115 frequently consumed foods, alongside IgG and IgA antibodies associated with gliadin, a gluten-related protein. The assessment is conducted using ELISA technology on a serum blood sample, offering a profile of immune responses that may reflect individual interactions with various dietary components. This test supports greater understanding of how the immune system may be engaged by a diverse range of foods and gluten-related proteins through measurable antibody activity.

Individuals interested in exploring connections between their diet and general wellbeing often consider this test. It can contribute to insights about possible food-related immune activity in relation to digestive comfort, skin condition, respiratory health, neurological function, or energy levels. When combined with personal dietary history, lifestyle factors, symptom tracking and other available health information, the results can inform reflective discussions about nutrition and wellness strategies tailored to individual nutritional interests and lifestyle goals.

Health and wellness practitioners typically integrate findings from the Immuno 1 IgG 115 + Gliadin test with a broad overview of personal health patterns. This comprehensive approach allows for meaningful exploration of dietary habits and their potential links to overall vitality and lifestyle optimisation. Such insights can facilitate informed engagement around food choices and support ongoing personal wellness management rather than clinical intervention or diagnosis.

Immuno 1 IgG 115 + Gliadin is intended for informational, educational, wellness and/or research purposes only. It is not intended for use in medical diagnosis, disease screening or clinical decision-making. Immuno 1 IgG 115 + Gliadin is not a replacement for clinical laboratory testing and does not provide medical diagnoses. This content is intended for general information within the EU market and should not be interpreted as a regulated in-vitro diagnostic claim.